BLAINTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERPriority Review
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
LAMZEDE (velmanase alfa-tycv) by Chiesi is alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in mannosidase alpha class 2b member 1. First approved in 2023.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMZEDE (velmanase alfa-tycv) is an enzyme replacement therapy for alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of alpha-mannosidase. The drug provides exogenous alpha-mannosidase that is internalized via mannose-6-phosphate receptor binding and transported to lysosomes to degrade accumulated mannose-rich oligosaccharides. This addresses the root biochemical defect in a genetically rare patient population.
Peak
Product is in peak commercial phase post-2023 approval; limited market size typical for rare disease indicates focused, specialized commercial team.
Mechanism of Action
Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. Alpha-mannosidase catalyzes the degradation of accumulated mannose-containing oligosaccharides. The deficiency of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
Started Feb 2025
5 enrolled
Alpha-Mannosidosis
Career Relevance
Roles on LAMZEDE are highly specialized, focused on ultra-rare disease management, patient education, and healthcare provider engagement in lysosomal storage disorder centers of excellence. Career growth depends on expertise in rare disease commercialization, genetic disorders, and complex patient-support logistics rather than mass-market brand experience.
Worked on LAMZEDE at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.